[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555553":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":42,"responsibleParty":61,"collaborators":65,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":44,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":37,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":37,"overallStatus":45,"whyStopped":37,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Xinjiang Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Superselective adrenal artery embolization group","EXPERIMENTAL","Superselective adrenal artery embolization for primary aldosteronism",[13],"Procedure: Superselective adrenal artery embolization or adrenalectomy",{"label":15,"type":16,"description":17,"interventionNames":18},"Adrenalectomy group","ACTIVE_COMPARATOR","Adrenalectomy for primary aldosteronism",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Superselective adrenal artery embolization or adrenalectomy","Arm A underwent SAAE treatment, and arm B underwent laparoscopic adrenalectomy.",[15,9],[26],"Adrenalectomy",[28],{"name":29,"affiliation":30,"role":31},"Ying-Ying Zheng, PhD","1st affiliatted hospital of Xinjiang Medical University","STUDY_CHAIR",[33,39],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"Xiang Xie, PhD","CONTACT","+869914366892",null,"xiangxie999@sina.com",{"name":40,"role":35,"phone":36,"phoneExt":37,"email":41},"Changjiang Deng","1187229853@qq.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"The First Affiliated Hospital of Xinjiang Medical University","RECRUITING","Ürümqi","Xinjiang","630000","China","CN",{"type":52,"coordinates":53},"Point",[54,55],87.60046,43.80096,{"lat":55,"lon":54},[58,60],{"name":59,"role":35,"phone":36,"phoneExt":37,"email":38},"Xiang xie",{"name":40,"role":35,"phone":36,"phoneExt":37,"email":41},{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":37,"oldOrganization":37},"PRINCIPAL_INVESTIGATOR","Xiang Xie","Head of Hypertension Department, Clinical Professor",[66],{"name":67,"class":6},"First Affiliated Hospital of Xinjiang Medical University","100555553","primary-aldosteronism-superselective-embolization-vs-laparoscopic-endocrine-curative-therapy-100555553",false,"NCT06513585","Primary Aldosteronism: Superselective Embolization vs. Laparoscopic Endocrine Curative Therapy","PA-SELECT","Inclusion Criteria:\n\n* Age 18-60\n* Diagnosed with primary aldosteronism according to the 2016 Clinical guidelines of the International Endocrine Society\n* Primary aldosteronism diagnosed according to international guidelines Unilateral disease by AVS or PET-CT criteria\n* Patients and their family members signed informed consent and agreed to participate in the study\n\nExclusion Criteria:\n\n* A history of severe hypersensitivity to contrast media\n* Severe liver disease complications, such as thrombocytopenia, esophageal varices rupture bleeding, etc\n* Renal insufficiency (serum creatinine \\> 176mmol\u002FL or estimated glomerular filtration rate \\\u003C min.1.73m2)\n* Combined with other secondary hypertension, such as pheochromocytoma, hypercortisolism, renal vascular hypertension (such as renal artery stenosis), renin secretory tumor, renal parenchymatous hypertension, drug-induced hypertension (such as long-term use of glucocorticoids, contraceptives, estrogen, herbal medicines containing glycyrrhizin), pregnancy hypertension and other secondary hypertension\n* Combined with genetic diseases: such as false aldosteronism (Liddle syndrome), Bartter syndrome, familial hypokalemia and hypomagnesia (Gitelman syndrome)\n* Stroke, myocardial infarction and stent implantation occurred in the past 3 months\n* Serious other diseases, such as heart dysfunction (grade IV), acute infections, autoimmune diseases, various malignant tumors, etc\n* Participated in other clinical trials within the past 3 months\n* Pregnant, breastfeeding, or planning a pregnancy\n* Identify patients with alcohol allergy","ALL","18 Years","60 Years",{"count":79,"type":80},570,"ESTIMATED","INTERVENTIONAL",[83],"NA","The aim of this study was to compare the efficacy and safety of adrenalectomy and superselective adrenal artery embolization in a prospective, multicenter, randomized controlled study. To provide a new interventional alternative therapy for primary aldosteronism.",[86,87,88],"Primary Aldosteronism","Suprarenalectomy","Super Selective Adrenal Artery Embolization","2025-04-14",{"date":91,"type":92},"2025-04-15","ACTUAL",{"date":94,"type":92},"2024-08-01",{"date":96,"type":80},"2026-12-01",{"name":5,"class":6},1]